Sign in Subscribe
Cancer

Novel Monoclonal Antibody Combination Shows Promising Efficacy in Advanced NSCLC

Strategic Insights

— 1 min read

Research conducted by the Duke Cancer Institute has led to the development of a novel combination of monoclonal antibodies, which demonstrated significant efficacy in patients with advanced non-small cell lung cancer (NSCLC). The study, titled "A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial," aimed to assess the safety and efficacy of this combination in patients with treatment-naive, advanced NSCLC.

The trial involved 46 patients, with a median age of 66 years and a median follow-up of 19 months. The primary end point of the study was median progression-free survival (PFS), which was achieved at 9.4 months (95% confidence interval [CI]: 5.9-16.6). The objective response rate for patients in the study was 47.8% (95% CI: 33.4-62.3), and the 12-month overall survival (OS) rate was 69.5% (95% CI: 53%-81%).

Key Takeaways:

  • The study demonstrated the efficacy of a combination of nivolumab, ipilimumab, and paclitaxel in patients with untreated metastatic NSCLC, with a median PFS of 9.4 months.
  • The objective response rate for patients in the study was 47.8%, indicating a significant improvement in tumor control.
  • The 12-month OS rate was 69.5%, suggesting a notable improvement in survival outcomes.
  • The toxicity observed in the study was consistent with other reported chemo-immunotherapeutic combinations and was manageable.
  • The study concludes that the combination of nivolumab, ipilimumab, and paclitaxel should be further evaluated in a randomized trial.

Statistics:

  • Median PFS: 9.4 months (95% CI: 5.9-16.6)
  • Objective response rate: 47.8% (95% CI: 33.4-62.3)
  • 12-month OS rate: 69.5% (95% CI: 53%-81%)
  • Median age of patients: 66 years (range: 48-82)
  • Number of patients who underwent consent and received treatment: 46

Sources:

  • NewsRx. Researchers at Duke Cancer Institute Publish New Study Findings on Monoclonal Antibodies (A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial). Immunotherapy Weekly. July 6, 2022; p 1232.
  • A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial. JTO Clinical and Research Reports, 2022,3(6):100337. (doi-org.sdpl.idm.oclc.org/10.1016/j.jtocrr.2022.100337)

Read more